Summary of Use during Lactation

No information is available on the clinical use of rasburicase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 34,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably partly destroyed in the infant's gastrointestinal tract.[1,2] However, the manufacturer recommends that breastfeeding be discontinued during rasburicase therapy and for 2 weeks after the final dose. An alternate drug can be considered.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Allopurinol, Probenecid

References

1.

Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003 [CrossRef]

2.

Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3. [PubMed: 33956488]

Substance Name

Rasburicase

CAS Registry Number

134774-45-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Enzymes

Gout Suppressants

Urate Oxidase